[1]张慧玮,赵军.18F-FDG代谢显像相关分子机制的研究进展[J].国际放射医学核医学杂志,2011,35(1):1-5.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
 ZHANG Hui-wei,ZHAO Jun.Progress of molecular mechanism of 18F-FDG metabolism imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):1-5.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
点击复制

18F-FDG代谢显像相关分子机制的研究进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第1期
页码:
1-5
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Progress of molecular mechanism of 18F-FDG metabolism imaging
作者:
张慧玮 赵军
复旦大学附属华山医院PET中心, 上海 200235
Author(s):
ZHANG Hui-wei ZHAO Jun
PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China
关键词:
氟脱氧葡萄糖F18糖酵解肿瘤
Keywords:
Fluorodeoxyglucose F18GlycolysisNeoplasms
DOI:
10.3760/cma.j.issn.1673-4114.2011.01.001
摘要:
18F-FDG作为最常用的PET-CT显像剂,被广泛应用于肿瘤显像。吸收和利用葡萄糖可以由多因素控制,它们都参与到肿瘤有氧糖酵解的增加,转移性肿瘤对FDG摄取普遍增加的现象提示它可能是必需的。高糖代谢是癌变的重要组成部分,因为糖代谢的增加产生了大量酸,酸给癌细胞提供生长的环境。理清FDG代谢的原理有利于更准确的影像诊断,与肿瘤对FDG高摄取相关的葡萄糖代谢主要分子机制包括葡萄糖转运蛋白和己糖激酶、线粒体缺陷、c-myc、缺氧诱导因子等。
Abstract:
18F-FDG is the most common PET-CT imaging agent, which is widely used in tumor inaging. Absorption and utilization of glucose can he controlled by multiple factors, which are involved in the increase in aerobic glycolysis of tumor. The phenomenon of a general increase uptake of FDG in metastatic tumor may indicate that it is necessary. High glucose metabolism is an important sign of cancer because increased glucose metabolism produces acid, which provide the growth environment to cancer cells. It is important to know the principle of FDG metabolism for accurate image diagnosis. This article reviews the progress of relevant molecular mechanism in recent years. The major molecular mechanism of glucose metabolism associated with tumor FDG uptake include glucose transport and hexokinase, mitochondrial defects, c-myc, hypoxia-inducible factor and so on.

参考文献/References:

[1] Warhurg O.On the origin of cancer cells. Sciene,1956, 123(3191):309-314.
[2] Gillies RJ, Robcy I, Gatenby RA. Gauses and consequences of increased glucose metabolism of cancers. J Nucl Med, 2008, 49(Suppl 2):24S-42S.
[3] Gambhir SS, Gzernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med, 2001, 42(5 Supp):1S-93S.
[4] 孟晓云,陈跃.葡萄糖转运蛋自的调控与疾病.医学综述,2008, 14(14):2097-2100.
[5] 赵迎超,伍钢.已糖激酶与恶性肿瘤关系的研究进展.肿瘤防治研究,2006,33(9):694-696.
[6] Rho M, Kim J, Jee CD, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res, 2007, 27(1A):251-258.
[7] Hervouet E, Godinot C. Mitochondrial disorders in renal tumors. Mitochondrion, 2006, 6(3):105-117.
[8] Lóipez-Rios F, Sáinchez-Aragó M, García-García E,et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res, 2007, 67(19):9013-9017.
[9] Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis, 2005, 26(12):2095-2104
[10] Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondrial bio-genesis and cellular respiration in VHL-deficient renal cell carci-noma by repression of C-MYC activity. Cancer Cell, 2007, 11(5):407-420.
[11] Krocmcr G.Mitochondria in cancer. Oncogene,2006, 25(34):4630-4632.
[12] Mazurc NM, Chauvet C, Bois-Joyeux B,et al. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells:characterization of a negative hypoxia response ele-ment that mediates opposite effects of hypoxia inducible factor-1 and c-Myc·Cancer Res, 2002, 62(4):1158-1165.
[13] Kim JW, Gao P, Liu YC,et al. Hypoxia-inducible factor 1 and dys-regulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydro-genase kinase 1. Mol Cell Biol, 2007, 27(21):7381-7393.
[14] Benassi B, Fanciulli M, Fiorentino F,et al. C-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell, 2006, 21(4):509-519.
[15] Osthus RC, Shim H, Kim S,et al. Deregulation of glucose trans-porter 1 and glycolytic gene expression by c-Myc.J Biol Chem, 2000, 275(29):21797-21800.
[16] 杨盛力,张万广,陈孝平,等.缺氧诱导因子-1与缺氧诱导因子-2同肿瘤关系的比较.肝胆外科杂志,2007, 15(6):471-474.
[17] Levine DA, Bogomolniy F, Yee CJ,et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res, 2005, 11(8):2875-2878.
[18] Knobbe CB, Tramps-Kieslich A, Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol, 2005, 31(5):486-490.
[19] Oda K, Stokoe D, Taketani Y,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res, 2005, 65(23):10669-10673.
[20] Hartmann W,Digon-Sontgerath B, Koch A,et al. Phosphatidylinos-itol 3’-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res,2006, 12(10):3019-3027.
[21] Or YY, Hui AB, Tam KY,et al. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol, 2005, 26(1):49-56.
[22] Nyakern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia, 2006, 20(2):230-238.
[23] Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor sup-pressor induces cell death that is rescued by the AKT protein kinase B oncogene.Cancer:Res, 1998, 58(24):5667-5672.
[24] Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100(4):387-390.
[25] Buzzai M, Bauer DE, Jones RG,et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene,2005, 24(26):4165-4173.
[26] Vivanco,I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer, 2002, 2(7):489-501.
[27] Matoba S, Kung JG, Patino WD, et al. p53 regulate、mitochondrial respiration. Science,2006, 312(5780):1650-1653.
[28] Bensaad K, Vousden KH. p53:new roles in metabolism. Trends Cell Biol, 2007, 17(6):286-291.
[29] Bensaad K, Tsuruta A, Sclak MA,et al. TIGAR,a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006, 126(1):107-120.
[30] Green DR, Chipuk JE. p53 and metabolism:Inside the TIGAR. Cell, 2006, 126(1):30-32.

相似文献/References:

[1]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
 Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
 You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
 Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[4]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
 Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[5]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
 Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[6]曹登敏,林美福,陈文新,等.继发性骨淋巴瘤的18F-FDG PET/CT影像学表现[J].国际放射医学核医学杂志,2016,40(6):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
 Cao Dengmin,Lin Meifu,Chen Wenxin,et al.Analysis on 18F-FDG PET/CT imaging characteristics in secondary bone lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):403.[doi:10.3760/cma.j.issn.1673-4114.2016.06.001]
[7]李生栩,唐明灯,林端瑜,等.18F-FDG PET/CT在胸段食管鳞癌淋巴结转移中的诊断价值[J].国际放射医学核医学杂志,2016,40(6):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
 Li Shengxu,Tang Mingdeng,Lin Duanyu,et al.Value of 18F-FDG PET/CT in detecting metastatic lymph nodes of thoracic esophageal squamous cell carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):408.[doi:10.3760/cma.j.issn.1673-4114.2016.06.002]
[8]张莹莹,王振光,武凤玉,等.特发性肺间质纤维化HRCT病变区与非病变区18F-FDG PET/CT表现分析[J].国际放射医学核医学杂志,2016,40(6):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
 Zhang Yingying,Wang Zhenguang,Wu Fengyu,et al.18F-FDG PET/CT imaging analysis of regions with abnormal and normal pulmonary parenchyma on high resolution CT in idiopathic pulmonary fibrosis patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):414.[doi:10.3760/cma.j.issn.1673-4114.2016.06.003]
[9]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
 Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[10]郝新忠,武志芳,武萍,等.SAPHO综合征18F-FDG PET/CT显像和临床分析[J].国际放射医学核医学杂志,2015,39(6):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]
 Hao Xinzhong,Wu Zhifang,Wu Ping,et al.18F-FDG PET/CT imaging and clinical features of SAPHO syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):447.[doi:10.3760/cma.j.issn.1673-4114.2015.06.003]

备注/Memo

备注/Memo:
收稿日期:2010-08-02。
通讯作者:赵军(Email:petcentcr@163.com)
更新日期/Last Update: 1900-01-01